Login to Your Account

Other News To Note

Tuesday, March 15, 2011
Cellceutix Corp., of Beverly, Mass., reported that Formatech Inc., of Andover, Mass., has begun production of Kevetrin for clinical trials. Cellceutix is finalizing an investigational new drug application, which it hopes to submit in May to the FDA, for Kevetrin for the treatment of drug-resistant cancers. If approved, the drug compound would be the first in its class to be used as an anticancer agent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription